Categories: News

NYSE Content Advisory: Pre-Market update + S&P 500 hits 28th record in 2025

NEW YORK, Sept. 23, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Ashley Mastronardi delivers the pre-market update on September 23rd

- Advertisement -
  • Stocks are little changed Tuesday morning after the S&P 500 hit its 28th record of the year. The large cap index was helped by Nvidia’s plans to invest $100 billion into Open AI.
  • NYSE-listed Oracle jumped by more than 6% to begin the week after it named two new co-CEOs. Shares of the stock are up by nearly 40% over the past month after releasing bullish cloud infrastructure guidance in September.
  • Wall Street is preparing for August’s PCE reading on Friday morning. This report will give investors the latest update on the state of the U.S. economy and help guide the Fed’s monetary policy decisions.

Opening Bell
CompoSecure Holdings (NYSE: CMPO) celebrates its transfer to the NYSE

- Advertisement -

Closing Bell
Resolute Holdings (NYSE: RHLD) celebrates its transfer to the NYSE

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2779788/NYSE_Sept_23_Market_Update.mp4 
Logo – https://mma.prnewswire.com/media/2581322/5525278/New_York_Stock_Exchange_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–sp-500-hits-28th-record-in-2025-302564420.html

- Advertisement -

Recent Posts

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

3 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

3 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

3 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

3 hours ago